PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair ...

PARP inhibitors (e.g., Olaparib ... increase our understanding of mechanisms underlying ischemic stroke risk with periodontitis; and b) identify new therapeutic targets to reduce ischemic stroke in ...